Neoadjuvant Immunotherapy to ESCC

Esophagus SCC Clinical Trial

Official title: Neoadjuvant Immunotherapy Combined With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Cancer: an Open Label, Randomized Control, Phase II Trial

Status Withdrawn

Clinical Trial Summary

Currently, surgery after neoadjuvant chemoradiotherapy is the standard treatment for patients with locally advanced esophageal cancer, but the recurrence rate is high and the 5-year survival rate is low. Immunotherapy shows a potential treatment for esophageal cancer. Immunocheckpoint (PD-1/PD-L1) inhibitors can activate tumor immunity. The guidelines have recommended it as a sencond-line therapy. However, there is still lack of the evidence for its efficacy as a neoadjuvant therapy. This study is to conduct a randomized controlled, open label, phase II clinical trial to evaluate the efficacy and safety of neoadjuvant immnotherapy combined with neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma (ESCC) patient with PD-L1 (CPS>=10%) positive.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Esophageal Squamous Cell Carcinoma
• Esophagus SCC

• NCT number: NCT04625543
• Study type: Interventional
• Source: Qilu Hospital of Shandong University
• Status: Withdrawn
• Phase: Phase 2
• Start date: December 2020
• Completion date: September 2023